澤璟製藥(688266.SH)業績快報:2020年度淨虧損3.18億元
格隆匯 2 月 25日丨澤璟製藥(688266.SH)發佈2020年度業績快報,實現營業收入2766.09萬元,歸屬於母公司所有者的淨利潤為-31836萬元,虧損同比減少;歸屬於母公司所有者的扣除非經常性損益的淨利潤為-35362.34萬元,虧損同比增長。
截至快報披露日,公司1類新藥甲苯磺酸多納非尼片用於治療晚期(無法手術或轉移性)肝細胞癌適應症的新藥上市申請(NDA)正在審批中;報吿期內,公司尚無藥品獲得商業銷售批准,未產生藥品銷售收入,公司已實現營業收入系抗體產品對外授權許可收入及少量研發技術服務收入;公司研發的多個創新藥物項目穩步推進,研發團隊建設不斷加強,研發投入持續增加;同時,公司開展新藥商業化銷售團隊建設和上市前期市場拓展準備工作等各項開支增加。因此,公司2020 年度仍未實現盈利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.